68Ga-HA-DOTATATE

68Ga-HA-DOTATATE is a radiopharmaceutical designed for positron emission tomography (PET) imaging, primarily used for the detection and localization of somatostatin receptor-positive neuroendocrine tumors (NETs). It functions as a somatostatin analog, binding with high affinity to somatostatin receptors, particularly subtype 2 (SSTR2), which are frequently overexpressed on the surface of NET cells. The compound consists of the peptide HA-DOTATATE, which targets the somatostatin receptors, chelated with the radioactive isotope Gallium-68 (68Ga). Upon intravenous administration, 68Ga-HA-DOTATATE circulates and selectively accumulates in tumor cells expressing SSTR2. The Gallium-68 then emits positrons, which are detected by a PET scanner to create detailed images, allowing clinicians to visualize and assess the extent of these tumors. This diagnostic agent is currently in clinical development, with studies evaluating its safety and efficacy in various SSTR-positive tumor types.

Other names

[(68)Ga]DOTA-3-iodo-Tyr(3)-octreotate